Ceccarelli M, Venanzi Rullo E, Marino MA, d’Aleo F, Pellicanò GF, D’Andreaet F, et al. Non-AIDS defining cancers: a comprehensive update on diagnosis and management. Eur Rev Med Pharmaco. 2020;24:3849–75. https://doi.org/10.26355/eurrev_202004_20852.

Article  CAS  Google Scholar 

Shiels MS, Islam JY, Rosenberg PS, Hall HI, Jacobson E, Engels EA, et al. Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030. Ann Intern Med. 2018;168:866–73. https://doi.org/10.7326/M17-2499.

Article  PubMed  PubMed Central  Google Scholar 

Di Benedetto F, De Ruvo N, Berretta M, Masetti M, Montalti R, Di Sandro S, et al. Don’t deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol. 2006;24:e26–7. https://doi.org/10.1200/JCO.2006.06.1374.

Article  PubMed  Google Scholar 

Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370:59–67. https://doi.org/10.1016/S0140-6736(07)61050-2.

Article  PubMed  Google Scholar 

Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148:728–36. https://doi.org/10.7326/0003-4819-148-10-200805200-00005.

Article  PubMed  Google Scholar 

Alfa-Wali M, Tait D, Allen-Mersh T, Tekkis P, Nelson M, Stebbing J, et al. Colorectal cancer in HIV positive individuals: the immunological effects of treatment. Eur J Cancer. 2011;47:2403–7. https://doi.org/10.1016/j.ejca.2011.06.036.

Article  PubMed  Google Scholar 

Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2015;33:2376–83. https://doi.org/10.1200/JCO.2014.59.5967.

Article  PubMed  PubMed Central  Google Scholar 

Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492–9. https://doi.org/10.1038/ni.2035.

Article  CAS  PubMed  Google Scholar 

Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–82. https://doi.org/10.1200/JCO.2014.59.4358.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou WP, Wolchok JD, Chen LP. PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4. https://doi.org/10.1126/scitranslmed.aad7118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26:1027–32. https://doi.org/10.1200/JCO.2007.14.5532.

Article  PubMed  Google Scholar 

Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893–900. https://doi.org/10.1038/nm.1972.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis. 2013. https://doi.org/10.1093/infdis/jis630.

Article  PubMed  PubMed Central  Google Scholar 

Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, et al. Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. AIDS. 2014;28:1749–58. https://doi.org/10.1097/QAD.0000000000000314.

Article  CAS  PubMed  Google Scholar 

Zhang JY, Zhang Z, Wang XC, Fu JL, Yao JX, Jiao YM, et al. PD-1 up-regulation is correlated with HIV-specificmemory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressos. Blood. 2007;109:4671–4618. https://doi.org/10.1182/blood-2006-09-044826.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378:1029–41. https://doi.org/10.1056/NEJMra1615896.

Article  PubMed  PubMed Central  Google Scholar 

Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123:187–94. https://doi.org/10.1002/ijc.23487.

Article  CAS  PubMed  Google Scholar 

Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med. 2011;3:581–92. https://doi.org/10.1002/emmm.201100165.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–42. https://doi.org/10.1111/j.1600-065X.2010.00923.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007;8:1246–54. https://doi.org/10.1038/ni1515.

Article  CAS  PubMed  Google Scholar 

Lurain K, Ramaswami R, Mangusan R, Widell A, Ekwede I, George J, et al. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma. J Immunother Cancer. 2021;9:e002097. https://doi.org/10.1136/jitc-2020-002097.

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez-Cao M, Martinez-Picado J, Karachaliou N, Rosell R, Meyerhans A. Cancer immunotherapy of patients with HIV infection. Clin Transl Oncol. 2019;21:713–20. https://doi.org/10.1007/s12094-018-1981-6.

Article  CAS  PubMed  Google Scholar 

Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol. 2019;5:1049–54. https://doi.org/10.1001/jamaoncol.2018.6737.

Article  PubMed  Google Scholar 

Gonzalez-Cao M, Morán T, Dalmau J, Garcia-Corbacho J, Bracht JWP, Bernabe R, et al. Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study. JAMA Oncol. 2020;6:1063–7. https://doi.org/10.1001/jamaoncol.2020.0465.

Article  PubMed  PubMed Central  Google Scholar 

Bari S, Muzaffar J, Chan A, Jain SR, Haider AM, Curry MA, et al. Outcomes of programmed cell death protein 1 (PD-1) and programmed death-ligand 1(PD-L1) inhibitor therapy in HIV patients with advanced cancer. J Oncol. 2019. https://doi.org/10.1155/2019/2989048.

Article  PubMed  PubMed Central  Google Scholar 

Wang CY, Liu J, Lei H, Li Y, Wu J, Guo BL, et al. Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China. J Cell Mol Med. 2022;26:5067–77. https://doi.org/10.1111/jcmm.17534.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dittus C, Grover N, Sethi T, Cohen JB, Voloschin A, Rabadey J, et al. A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficienc virus. EJHaem. 2022;3:734–8. https://doi.org/10.1002/jha2.474.

Article  PubMed  PubMed Central  Google Scholar 

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39. https://doi.org/10.1056/NEJMoa1507643.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35. https://doi.org/10.1056/NEJMoa1504627.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84. https://doi.org/10.1016/S1470-2045(15)70076-8.

Article  CAS  PubMed  Google Scholar 

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30. https://doi.org/10.1056/NEJMoa1412082.

Article  CAS  PubMed  Google Scholar 

Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol. 2019;71:900–7. https://doi.org/10.1016/j.jhep.2019.06.028.

Article  CAS  PubMed  Google Scholar 

Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12:1198–202. https://doi.org/10.1038/nm1482.